Prognostic models: A methodological framework and review of models for breast cancer

Breast Cancer: Translational Therapeutic Strategies

Volumn , Issue , 2007, Pages 11-25

  Altman, Douglas G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61449097715     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (56)

1. Clark GM. Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 1994; 30(2):117-126.
2. Williams C, Brunskill S, Altman D, et al. Cost effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy of breast cancer. Health Technol Assess 2006; 10(34):1-222.
3. Wyatt JC, Altman DG. Commentary: prognostic models: clinically useful or quickly forgotten? Brit Med J 1995; 311:1539-1541.
4. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000; 19:453-473.
5. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JD. Validity of prognostic models: when is a model clinically useful? Semin Urol Oncol 2002; 20(2):96-107.
6. Redelmeier DA, Lustig AJ. Prognostic indices in clinical practice. J Am Med Assoc 2001; 285(23):3024-3025.
7. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariate models. Ann Intern Med 1993; 118(201):210.
8. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69(6):979-985.
9. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998; 52:289-303.
10. Schumacher M, Hollander N, Schwarzer G, Sauerbrei W. Prognostic factor studies. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York: Marcel Dekker, 2001:321-378.
11. Schmoor C, Sauerbrei W, Schumacher M. Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 2000; 19:441-452.
12. McShane LM, Simon R. Statistical methods for the analysis of prognostic factor studies. In: Gospodarowicz MK, Henson DE, Hutter RVP, et al., eds. Prognostic Factors in Cancer. New York: Wiley-Liss, 2001:37-48.
13. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985; 69(10):1071-1077.
14. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48(12):1503-1510.
15. Feinstein AR. Multivariable Analysis: An Introduction. New Haven: Yale University Press, 1996.
16. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991; 83(3):154-155.
17. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection bias with tumor tissue retrieval in molecular epidemiology studies. Ann Epidemiol 2002; 12(1):1-6.
18. Burton A, Altman D. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. Brit J Cancer 2004; 91:4-8.
19. Altman DG. Suboptimal analysis using "optimal" cutpoints. Brit J Cancer 1998; 78(4):556-557.
20. Bossard N, Descotes F, Bremond AG, et al. Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer. Breast Cancer Res Treat 2003; 82:47-59.
21. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25(1):127-141.
22. Morgan TM, Elashoff FA. Effect of categorizing a continuous covariate on the comparison of survival time. J Am Stat Assoc 1986; 81:917-921.
23. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992; 22(3):197-206.
24. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cut-points in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86(11):829-835.
25. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: Multivariate data analysis-an introduction to concepts and methods. Brit J Cancer 2003; 89:431-436.
26. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportionalodds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002; 21(15):2175-2197.
27. Nardi A, Schemper M. Comparing Cox and parametric models in clinical studies. Stat Med 2003; 22(23):3597-3610.
28. Elston EW, Ellis IO. Method for grading breast cancer. J Clin Pathol 1993; 46(2):189-190.
29. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004; 23(5):723-748.
30. Burke HB, Goodman PH, Rosen DB, et al. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer 1997; 79(4):857-862.
31. Lockwood CA, Ricciardelli C, Raymond WA, Seshadri R, McCaul K, Horsfall DJ. A simple index using video image analysis to predict disease outcome in primary breast cancer. Int J Cancer 1999; 84(3):203-208.
32. Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC. A prognostic index in primary breast cancer. Brit J Cancer 1982; 45:361-366.
33. Galea MH, Blamey RW, Elston CW, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992; 22(3):207-219.
34. Todd JH, Dowle C, Williams MR, et al. Confirmation of a prognostic index in primary breast cancer. A. Brit J Cancer 1987; 56(4):489-492.
35. Guerra I, Algorta J, Diaz dO, Pelayo A, Farina J. Immunohistochemical prognostic index for breast cancer in young women. Mol Pathol 2003; 56(6):323-327.
36. Kollias J, Murphy CA, Elston CW, Ellis IO, Robertson JFR, Blamey RW. The prognosis of small primary breast cancers. Eur J Cancer 1999; 35(6):908-912.
37. Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG). Breast Cancer Res Treat 1994; 32(3):281-290.
38. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: prognostic significance in breast cancer. Br J Cancer 2000; 82(2):339-347.
39. Sundquist M, Thorstenson S, Brudin L, Nordenskjold B. Applying the Nottingham Prognostic Index to a Swedish breast cancer population. South East Swedish Breast Cancer Study Group. Breast Cancer Res Treat 1999; 53(1):1-8.
40. Collett K, Skjaerven R, Maehle BO. The prognostic contribution of estrogen and progesterone receptor status to a modified version of the Nottingham Prognostic Index. Breast Cancer Res Treat 1998; 48(1):1-9.
41. Collan Y, Kumpusalo L, Pesonen E, Eskelinen M, Pajarinen P, Kettunen K. Prediction of survival in breast cancer: evaluation of different multivariate models. Anticancer Res 1998; 18(1B):647-650.
42. Baak JPA, Van Dop H, Kurver PHJ, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer 1985; 56(2):374-382.
43. Vollmer RT. Malignant melanoma. A multivariate analysis of prognostic factors. Pathol Ann 1989; 24(Pt 1):383-407.
44. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol 2001; 165(5):1562-1568.
45. Vollmer RT, Keetch DW, Humphrey PA. Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. Cancer 1998; 83(8):1567-1580.
46. Gobbi PG, Zinzani PL, Broglia C, et al. Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer 2001; 91(8):1467-1478.
47. Counsell C, Dennis M. Systematic reviews of prognostic models in patients with acute stroke. Cerebrovasc Dis 2001; 12:159-170.
48. Clark TG, Altman DG. Developing a prognostic model in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol 2003; 56(1):28-37.
49. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med 1992; 11(16):2093-2109.
50. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Brit J Cancer 1995; 72(2):511-518.
51. Riley RD, Burchill SA, Abrams KR, et al. A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. Eur J Cancer 2003; 39:19-30.
52. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97(16):1180-1184.
53. Parham DM, Hagen N, Brown RA. Simplified method of grading primary carcinomas of the breast. J Clin Pathol 1992; 45(6):517-520.
54. Graf E, Schmoor C, Sauerbrei W, Schumacher M. Assessment and comparison of prognostic classification schemes for survival data. Stat Med 1999; 18(17/18):2529-2545.
55. Haybittle JL. Prognostic indices in breast cancer. Colloques et Seminaires 1986; 137: 779-787.
56. Blamey RW. The design and clinical use of the Nottingham prognostic index in breast cancer. Breast 1996; 5:156-157.